^
    Back
    Association details:
    Biomarker:VHL mutation
    Cancer:Clear Cell Renal Cell Carcinoma
    Drug:MK-3795 (HIF-2α antagonist)
    Direction:Sensitive
    Evidence:
    Evidence Level:
    Sensitive: C2 – Inclusion Criteria
    Go to data
    Source:
    clinicaltrials.gov
    Title:

    PT2385 for the Treatment of Von Hippel-Lindau Disease-Associated Clear Cell Renal Cell Carcinoma

    Excerpt:
    ...Overall response rate (ORR) in VHL disease-associated ccRCC tumors...Has a diagnosis of von Hippel Lindau disease, based on a germline VHL alteration...
    Trial ID:
    NCT03108066
    Evidence Level:
    Sensitive: C3 – Early Trials
    Source:
    SUO 2020
    Title:

    RESULTS OF AN OPEN LABEL PHASE II CLINICAL TRIAL OF A HIF-2ALPHA INHIBITOR (PT2385) IN VON HIPPEL-LINDAU ASSOCIATED CLEAR CELL RENAL CELL CARCINOMA.

    Published date:
    11/20/2020
    Excerpt:
    PT2385 was administered orally at a dose of 800 mg twice daily....PT2385 demonstrated stabilization of disease in VHL-associated clear cell RCC and other tumors.
    Trial ID:
    NCT03108066